CIK 0002143850 · <br>Emerging growth company
CITY THERAPEUTICS, INC.
Sign in to watch- Ticker
- CTY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- other
- EIN
- 932762122
- Phone
- 857-357-2024
- Business address
- 399 BINNEY ST, CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $6,120,000
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$6,120,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-19 | ARCH Venture Partners XII, LLC 10% owner | Conversion | +3,294,900 | 6,013,192 | ||
| 2026-10-19 | ARCH Venture Partners XII, LLC 10% owner | Conversion | +5,482,309 | 11,495,501 | ||
| 2026-10-19 | ARCH Venture Partners XII, LLC 10% owner | Conversion | +2,027,006 | 13,522,507 | ||
| 2026-10-19 | ARCH Venture Partners XII, LLC 10% owner | Purchase | +170,000 | $18.00 | $3.1M | 13,692,507 |
| 2026-10-19 | ARCH Venture Partners XII, LLC 10% owner | Conversion · Series Seed convertible preferred stock | −3,000,000 | 0 | ||
| 2026-10-19 | ARCH Venture Partners XII, LLC 10% owner | Conversion · Series A convertible preferred stock | −4,991,633 | 0 | ||
| 2026-10-19 | ARCH Venture Partners XII, LLC 10% owner | Conversion · Series B convertible preferred stock | −1,845,585 | 0 | ||
| 2026-10-19 | NELSEN ROBERT Director | Conversion | +3,294,900 | 6,013,192 | ||
| 2026-10-19 | NELSEN ROBERT Director | Conversion | +5,482,309 | 11,495,501 | ||
| 2026-10-19 | NELSEN ROBERT Director | Conversion | +2,027,006 | 13,522,507 | ||
| 2026-10-19 | NELSEN ROBERT Director | Purchase | +170,000 | $18.00 | $3.1M | 13,692,507 |
| 2026-10-19 | NELSEN ROBERT Director | Conversion · Series Seed convertible preferred stock | −3,000,000 | 0 | ||
| 2026-10-19 | NELSEN ROBERT Director | Conversion · Series A convertible preferred stock | −4,991,633 | 0 | ||
| 2026-10-19 | NELSEN ROBERT Director | Conversion · Series B convertible preferred stock | −1,845,585 | 0 | ||
| 2026-10-19 | MARAGANORE JOHN Director | Conversion | +610,759 | 1,470,692 | ||
| 2026-10-19 | MARAGANORE JOHN Director | Conversion · Series Seed convertible preferred stock | −500,000 | 0 | ||
| 2026-10-19 | MARAGANORE JOHN Director | Conversion · Series A convertible preferred stock | −56,095 | 0 | ||
| 2026-10-19 | ORTH ANDREW C. President & CEO | Grant or award · Stock Option (Right to Buy) | +77,979 | 77,979 | ||
| 2026-10-15 | NELSEN ROBERT Director | Grant or award · Stock Option (Right to Buy) | +22,649 | 22,649 | ||
| 2026-10-15 | MARAGANORE JOHN Director | Grant or award · Stock Option (Right to Buy) | +22,649 | 22,649 |
Page 1 of 2 · 23 trades